Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model

Channels

Volumn 6, Issue 1, 2012, Pages

  Brittain, Joel M ^a   Pan, Rui ^b   You, Haitao ^c   Brustovetsky, Tatiana ^a   Brustovetsky, Nickolay ^a   Zamponi, Gerald W ^c   Lee, Wei Hua ^a   Khanna, Rajesh ^a,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF CALGARY   (Canada)

^d Sophia Therapeutics LLC   (United States)

Author keywords

CRMP 2; Focal cerebral ischemia; MCAO model; N methylD aspartate receptor; Peptide

Indexed keywords

COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; POSTSYNAPTIC DENSITY PROTEIN 95; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN CBD3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PROTEIN PROTEIN INTERACTION; RAT;

ANIMALIA; RATTUS;

EID: 84860334997     PISSN: 19336950     EISSN: 19336969     Source Type: Journal    
DOI: 10.4161/chan.6.1.18919     Document Type: Article

References (43)

1. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984; 43:1369-74; PMID: 6149259; http://dx.doi.org/10.1111/j.1471- 4159.1984.tb05396.x
2. Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989; 244:798-800; PMID:2567056; http://dx.doi.org/10.1126/science.2567056
3. Villmann C, Becker CM. On the hypes and falls in neuroprotection: Targeting the NMDA receptor. Neuroscientist 2007; 13:594-615; PMID:17911221; http://dx.doi.org/10.1177/1073858406296259
4. Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006; 6:53-60; PMID:16359918; http://dx.doi.org/10.1016/j.coph.2005.12.002
5. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33:1834-9; PMID:12105362; http://dx.doi.org/10.1161/01.STR.0000020094.08790.49
6. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348:1333-41; PMID:12672860; http://dx.doi.org/10.1056/NEJMoa013128
7. Brittain JM, Chen L, Wilson SM, Brustovetsky T, Gao X, Ashpole NM, et al. Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2). J Biol Chem 2011; 286:37778-92; PMID:21832084; http://dx.doi.org/10.1074/jbc.M111.255455
8. Schmidt EF, Strittmatter SM. The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol 2007; 600:1-11; PMID:17607942; http://dx.doi.org/10.1007/978-0-387-70956-7-1
9. Hensley K, Venkova K, Christov A, Gunning W, Park J. Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol 2011; 43:180-91; PMID:21271304; http://dx.doi.org/10.1007/s12035-011-8166-4
10. Brittain JM, Piekarz AD, Wang Y, Kondo T, Cummins TR, Khanna R. An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels. J Biol Chem 2009; 284:31375-90; PMID:19755421; http://dx.doi.org/10. 1074/jbc.M109.009951
11. Chi XX, Schmutzler BS, Brittain JM, Wang Y, Hingtgen CM, Nicol GD, et al. Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons. J Cell Sci 2009; 122:4351-62; PMID:19903690; http://dx.doi.org/10.1242/jcs.053280
12. Wang Y, Brittain JM, Wilson SM, Khanna R. Emerging roles of collapsin response mediator proteins (CRMPs) as regulators of voltage-gated calcium channels and synaptic transmission. Commun Integr Biol 2010; 3:172-5; PMID:20539778; http://dx.doi.org/10.4161/cib.3.2.10620
13. Brittain JM, Duarte DB, Wilson SM, Zhu W, Ballard C, Johnson PL, et al. Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca(2) channel complex. Nat Med 2011; 17:822-9; PMID:21642979; http://dx.doi.org/10.1038/nm.2345
14. Wilson SM, Brittain JM, Piekarz AD, Ballard CJ, Ripsch MS, Cummins TR, et al. Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex. Channels 2011; 5:449-56; PMID:21829088; http://dx.doi.org/10.4161/chan.5.5.17363
15. Hou ST, Jiang SX, Aylsworth A, Ferguson G, Slinn J, Hu H, Leung T, Kappler J, Kaibuchi K. CaMKII phosphorylates collapsin response mediator protein 2 and modulates axonal damage during glutamate excitotoxicity. J Neurochem 2009; 111:870-81; PMID:19735446; http://dx.doi.org/10.1111/j.1471-4159.2009. 06375.x
16. Zhang Z, Ottens AK, Sadasivan S, Kobeissy FH, Fang T, Hayes RL, et al. Calpain-mediated collapsin response mediator protein-1, -2, and -4 proteolysis after neurotoxic and traumatic brain injury. J Neurotrauma 2007; 24:460-72; PMID:17402852; http://dx.doi.org/10.1089/neu.2006.0078
17. Touma E, Kato S, Fukui K, Koike T. Calpain-mediated cleavage of collapsin response mediator protein(CRMP)-2 during neurite degeneration in mice. Eur J Neurosci 2007; 26:3368-81; PMID:18052987; http://dx.doi.org/10.1111/j.1460-9568. 2007.05943.x
18. Bretin S, Rogemond V, Marin P, Maus M, Torrens Y, Honnorat J, et al. Calpain product of WT-CRMP2 reduces the amount of surface NR2B NMDA receptor subunit. J Neurochem 2006; 98:1252-65; PMID: 16787405; http://dx.doi.org/10. 1111/j.1471-4159. 2006.03969.x
19. Chung MA, Lee JE, Lee JY, Ko MJ, Lee ST, Kim HJ. Alteration of collapsin response mediator protein-2 expression in focal ischemic rat brain. Neuroreport 2005; 16:1647-53; PMID:16189471; http://dx.doi.org/10.1097/01.wnr.0000176520. 49841.e6
20. Al-Hallaq RA, Conrads TP, Veenstra TD, Wenthold RJ. NMDA di-heteromeric receptor populations and associated proteins in rat hippocampus. J Neurosci 2007; 27:8334-43; PMID:17670980; http://dx.doi.org/10.1523/JNEUROSCI.2155-07. 2007
21. Kloda A, Martinac B, Adams DJ. Polymodal regulation of NMDA receptor channels. Channels (Austin) 2007; 1:334-43; PMID:18690040
22. Brittain JM, Chen L, Wilson SM, Brustovetsky T, Gao X, Ashpole NM, et al. Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2). J Biol Chem 2011; 286:37778-92; PMID:21832084; http://dx.doi.org/10.1074/jbc.M111.255455
23. Bordi F, Pietra C, Ziviani L, Reggiani A. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat. Exp Neurol 1997; 145:425-33; PMID:9217078; http://dx.doi.org/10.1006/exnr.1997.6442
24. Dawson DA, Graham DI, McCulloch J, Macrae IM. Anti-ischaemic efficacy of a nitric oxide synthase inhibitor and a N-methyl-D-aspartate receptor antagonist in models of transient and permanent focal cerebral ischaemia. Br J Pharmacol 1994; 113:247-53; PMID:7529111
25. Sauter A, Rudin M. Strain-dependent drug effects in rat middle cerebral artery occlusion model of stroke J Pharmacol Exp Ther 1995; 274:1008-13; PMID: 7636715
26. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol 1988; 24:543-51; PMID:2853604; http://dx.doi.org/10.1002/ana.410240411
27. Indraswari F, Wong PT, Yap E, Ng YK, Dheen ST. Upregulation of Dpysl2 and Spna2 gene expression in the rat brain after ischemic stroke. Neurochem Int 2009; 55:235-42; PMID:19524114; http://dx.doi.org/10.1016/j.neuint.2009.03.005
28. Derugin N, Ferriero DM, Vexler ZS. Neonatal reversible focal cerebral ischemia: A new model. Neurosci Res 1998; 32:349-53; PMID:9950062; http://dx.doi.org/10.1016/S0168-0102(98)00096-0
29. Bu X, Zhang N, Yang X, Liu Y, Du J, Liang J, et al. Proteomic analysis of cPKCbetaII-interacting proteins involved in HPC-induced neuroprotection against cerebral ischemia of mice. J Neurochem 2011; 117: 346-56; PMID:21291475; http://dx.doi.org/10.1111/j.1471-4159.2011.07209.x
30. Takahara A, Konda T, Enomoto A, Kondo N. Neuroprotective effects of a dual L/N-type Ca(2+) channel blocker cilnidipine in the rat focal brain ischemia model. Biol Pharm Bull 2004; 27:1388-91; PMID:15340224; http://dx.doi.org/10. 1248/bpb.27.1388
31. Lee LL, Galo E, Lyeth BG, Muizelaar JP, Berman RF. Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker. Exp Neurol 2004; 190:70-8; PMID:15473981; http://dx.doi.org/10.1016/j.expneurol.2004.07.003
32. Perez-Pinzon MA, Yenari MA, Sun GH, Kunis DM, Steinberg GK. SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J Neurol Sci 1997; 153:25-31; PMID:9455974; http://dx.doi.org/10.1016/S0022-510X(97)00196-2
33. Bowersox SS, Singh T, Luther RR. Selective blockade of N-type voltage-sensitive calcium channels protects against brain injury after transient focal cerebral ischemia in rats. Brain Res 1997; 747:343-7; PMID: 9046013; http://dx.doi.org/10.1016/S0006-8993(96)01325-X
34. Valentino K, Newcomb R, Gadbois T, Singh T, Bowersox S, Bitner S, et al. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc Natl Acad Sci USA 1993; 90:7894-7; PMID:8102803; http://dx.doi.org/10.1073/pnas.90.16.7894
35. Kornau HC, Schenker LT, Kennedy MB, Seeburg PH. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 1995; 269:1737-40; PMID:7569905; http://dx.doi.org/10.1126/science. 7569905
36. Niethammer M, Kim E, Sheng M. Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J Neurosci 1996; 16: 2157-63; PMID:8601796
37. Martel MA, Soriano FX, Baxter P, Rickman C, Duncan R, Wyllie DJ, et al. Inhibiting pro-death NMDA receptor signaling dependent on the NR2 PDZ ligand may not affect synaptic function or synaptic NMDA receptor signaling to gene expression. Channels (Austin) 2009; 3:12-5; PMID:19221512; http://dx.doi.org/10. 4161/chan.3.1.7864
38. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science 2002; 298:846-50; PMID:12399596; http://dx.doi.org/10. 1126/science.1072873
39. Ryan TJ, Emes RD, Grant SG, Komiyama NH. Evolution of NMDA receptor cytoplasmic interaction domains: implications for organisation of synaptic signalling complexes. BMC Neurosci 2008; 9:6; PMID:18197970; http://dx.doi.org/10.1186/1471-2202-9-6
40. Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG. Proteomic analysis of NMDA receptoradhesion protein signaling complexes. Nat Neurosci 2000; 3:661-9; PMID:10862698; http://dx.doi.org/10.1038/76615
41. Bordet T, Pruss RM. Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain. Neurotherapeutics 2009; 6:648-62; PMID:19789070; http://dx.doi.org/10.1016/j.nurt.2009.07.001
42. Gonzalez FF, McQuillen P, Mu D, Chang Y, Wendland M, Vexler Z, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci 2007; 29:321-30; PMID: 17762200; http://dx.doi.org/10.1159/ 000105473
43. Brustovetsky T, Li V, Brustovetsky N. Stimulation of glutamate receptors in cultured hippocampal neurons causes Ca2+-dependent mitochondrial contraction. Cell Calcium 2009; 46:18-29; PMID:19409612; http://dx.doi.org/10.1016/j.ceca. 2009.03.017